Efavirenz, tenofovir and emtricitabine combined with irst-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: A pharmacokinetic and safety study

Antiviral Therapy

Volumn 18, Issue 1, 2013, Pages 105-113

  Semvua, Hadija H ^a   Mtabho, Charles M ^a   Fillekes, Quirine ^b   Van Den Boogaard, Jossy ^b   Kisonga, Riziki M ^c   Mleoh, Liberate ^c   Ndaro, Arnold ^a   Kisanga, Elton R ^a   Van Der Ven, Andre ^b   Aarnoutse, Rob E ^b   Kibiki, Gibson S ^a   Boeree, Martin J ^b   Burger, David M ^b  

^a KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Kibong'Oto National Tuberculosis Hospital   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TANZANIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BENZOXAZINES; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; ORGANOPHOSPHONATES; OXAZINES; PYRAZINAMIDE; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84874449099     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2413     Document Type: Article

References (39)

1. World Health Organization. Global tuberculosis control: WHO report 2011. Geneva: World Health Organization 2011.
2. Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: Opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367:926-937.
3. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009; 4:325-333.
4. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIVinfected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20:131-132.
5. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin Pharmacokinet 2003; 42:819-850.
6. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: An update. Arch Intern Med 2002; 162:985-992.
7. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40:327-341.
8. World Health Organisation. Treatment of tuberculosis: Guidelines. 4th Ed. Geneva: World Health Organisation 2010.
9. World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010 Revision. Geneva: World Health Organisation 2010.
10. Kwara A, Tashima KT, Dumond JB, et al. Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. Antimicrob Agents Chemother 2011; 55:3527-3533.
11. López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41:681-690.
12. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58:1299-1302.
13. Semvua HH, Kibiki GS. AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus. BMC Res Notes 2011; 4:511.
14. Aarnoutse RE, Grintjes KJ, Telgt DS, et al. The inluence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 2002; 71:57-67.
15. Droste JAH, Verweij-van Wissen CPWGM, Kearney BP, et al. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2005; 49:680-684.
16. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:1553-1560.
17. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampicin dose versus the standard dose in pulmonary tuberculois patients. Antimicrob Agents Chemother 2007; 51:2546-2551.
18. Williams RL, Chen ML, Hauck WW. Equivalence approaches. Clin Pharmacol Ther 2002; 72:229-237.
19. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
20. Cohen K, Grant A, Dandara C, et al. Effect of rifampicinbased antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14:687-695.
21. Ngaimisi E, Mugusi S, Minzi O, et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther 2011; 90:406-413.
22. Orrell C, Cohen K, Conradie F, et al. Efavirenz and rifampicin in the South African context: Is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther 2011; 16:527-534.
23. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, et al. CYP2B6 G516T polymorphism but not rifampin coadministration inluences steady-state pharmacokinetics of efavirenz in human immunodeiciency virus-infected patients in South India. Antimicrob Agents Chemother 2009; 53:863-868.
24. Kwara A, Lartey M, Sagoe KW, et al. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: Pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol 2008; 48:1032-1040.
25. Uttayamakul S, Likanonsakul S, Manosuthi W, et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther 2010; 7:8.
26. di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009; 19:300-309.
27. Haas DW, Gebretsadik T, Mayo G, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis 2009; 199:872-880.
28. Powers V, Ward J, Gompels M. CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: Polymorphism frequency and inluence on efavirenz discontinuation. HIV Med 2009; 10:520-523.
29. King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 2008; 22:1709-1717.
30. Nyakutira C, Roshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G-> T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008; 64:357-365.
31. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-662.
32. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15:861-873.
33. Friedland G, Churchyard GJ, Nardell E. Tuberculosis and HIV coinfection: Current state of knowledge and research priorities. J Infect Dis 2007; 196 Suppl 1:S1-S3.
34. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706.
35. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeiciency syndrome. Clin Pharmacol Ther 1993; 53:529-535.
36. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeiciency virus-infected adults. Antimicrob Agents Chemother 2001; 45:2733-2739.
37. Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosiscoinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 2011; 25:388-390.
38. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169-2183.
39. Lin MY, Lin SJ, Chan LC, Lu YC. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: Systematic review and meta-analysis. Int J Tuberc Lung Dis 2010; 14:806-818.